Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/221373
Title: | Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody−Associated Disease |
Author: | Villacieros Álvarez, Javier Espejo Ruiz, Carmen Arrambide, Georgina Dinoto, Alessandro Mulero Carrillo, Patricia Rubio Flores, Laura Nieto González, Pablo Alcalá, Carmen Meca Lallana, José E. Millan Pascual, Jorge Martínez García, Pedro Bernard Valnet, Raphael González Suárez, Inés Orviz García, Aída Téllez Pérez, Raquel Navarro Cantó, Laura Presas Rodríguez, Silvia Martínez Yélamos, Sergio Cuello, Juan Pablo Alonso Torres, Ana María Piñar Morales, Raquel Álvarez Bravo, Gary Benyahya, Lakhdar Trouillet Assant, Sophie Dyon Tafan, Virginie Froment Tilikete, Caroline Ruet, Aurélie Bourre, Bertrand Deschamps, Romain Papeix, Caroline Maillart, Elisabeth Kerschen, Philippe Ayrignac, Xavier Rovira, Àlex Auger Acosta, Cristina Audoin, Bertrand Montalbán Gairín, Xavier Tintoré Subirana, Mar Mariotto, Sara Cobo Calvo, Álvaro Marignier, Romain |
Keywords: | Neuroimmunologia Autoanticossos Neuroimmunology Autoantibodies |
Issue Date: | 1-Mar-2025 |
Publisher: | Ovid Technologies (Wolters Kluwer Health) |
Abstract: | Objectives To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) at onset and during follow-up and assess their utility for predicting relapses and disability. Methods This retrospective multicentric cohort study included patients aged 16 years and older meeting MOGAD 2023 criteria, with serum samples collected at baseline (<= 3 months from disease onset) and follow-up (>= 6 months from the baseline), and age-matched and time to sampling-matched patients with multiple sclerosis (MS). Eleven cytokines were assessed using the ELLA system. Data comparisons and statistical analyses between cytokine levels and clinical outcomes were performed. Results Eighty-eight patients with MOGAD and 32 patients with MS were included. Patients with MOGAD showed higher IL6 (p = 0.036), IL8 (p = 0.012), and IL18 (p = 0.026) baseline levels compared with those with MS, in non-optic neuritis (ON) presentations. BAFF values increased over time, especially in patients with MOGAD treated with anti-CD20 (p = 0.002). Baseline BAFF, CXCL10, IL10, and IL8 levels correlated with disease severity at MOGAD onset (all p < 0.05). Finally, higher baseline BAFF levels predicted lower risk of relapses (hazard ratio 0.41 [0.19; 0.89], p = 0.024). Discussion This study suggests a proinflammatory Th17-dominant profile in non-ON MOGAD patients, with a novel finding of a potential protective role of BAFF on relapses. These results shed new light on the pathogenesis of MOGAD, potentially guiding therapeutic decisions. |
Note: | Reproducció del document publicat a: https://doi.org/10.1212/NXI.0000000000200362 |
It is part of: | Neurology Neuroimmunology & Neuroinflammation, 2025, vol. 12, num. 2 |
URI: | https://hdl.handle.net/2445/221373 |
Related resource: | https://doi.org/10.1212/NXI.0000000000200362 |
ISSN: | 2332-7812 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
villacieros-álvarez-et-al-2025-profile-and-usefulness-of-serum-cytokines-to-predict-prognosis-in-myelin-oligodendrocyte.pdf | 395.26 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License